Cooperative Agreement UH3DA048371
Award Date 1/1/19
Completion Date 7/31/25
Dollars Obligated $10M
Federal Agency
Federal Grant Program
Assistance Type
Cooperative Agreement
Place of Performance
Mountain View, CA 94043, USA
Similar Awards
- Summary This Cooperative Agreement, awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $2.31 million to Virginia Commonwealth University to develop preliminary safety and early efficacy data for VVZ-2471, a novel 5-HT2A/mGluR5 (metabotropic glutamate receptor 5) antagonist as an adjunctive treatment for opioid use disorder (OUD). The award, announced on September 15, 2025, with completion by August 31, 2027,...
- The National Institute on Drug Abuse (NIDA) awarded a $7.99 million Cooperative Agreement to The Washington University (awarded September 1, 2025, with completion by August 31, 2027) under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop negative allosteric modulators (NAMs) at the mu opioid receptor as a therapeutic approach to treat opioid overdose and opioid use disorder (OUD). The research builds on the identification of a first-in-class NAM compound designated...
- This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $419,876 to conduct preclinical trials targeting the neuropeptide S (NPS) receptor to mitigate opioid taking and seeking behaviors in animal models. The goals of the project are to demonstrate proof-of-concept that NPS receptor-targeted molecules can reduce oxycodone self-administration and motivation in rats, which could inform the...
- Federal Cooperative Agreement Summary Mebias Discovery Inc. received a $9.42 million Cooperative Agreement from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) effective July 1, 2025, through June 30, 2027. The award funds the development and clinical evaluation of MEB-1170, a novel chemical entity designed to treat opioid use disorder (OUD) as a maintenance medication. The compound demonstrates a unique pharmacological profile as a...
- The National Institute on Drug Abuse (NIDA) awarded the University of Texas Health Science Center at Houston $2,085,384 on June 15, 2025, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct a pilot mechanistic study investigating semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), as a potential treatment for cocaine use disorder (CUD). This R01 Stage IIA project, which will conclude February 28, 2029, will generate proof-of-concept evidence demonstrating...
- Federal Grant Award Summary Boston Interactome LLC received a $398,137 Project Grant from the National Institute on Drug Abuse under the Drug Use and Addiction Research Programs (CFDA 93.279) beginning May 1, 2025, with a completion date of April 30, 2027. The company is developing high-precision epigenetic therapeutics targeting opioid use disorder (OUD), a critical public health concern for which current treatment options remain limited. The project leverages a novel protein-protein...
- Federal Cooperative Agreement Summary George Washington University received a $2.1 million Cooperative Agreement from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct research evaluating oxytocin (OXT), an FDA-approved medication, as a novel therapeutic intervention for opioid-induced respiratory depression (OIRD). The research initiative, awarded July 1, 2025, with completion expected June 30, 2027, addresses the critical...
- This Project Grant award of $201,960, funded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), supports a K99/R00 career development award at the University of Utah extending from July 1, 2025 through June 30, 2027. The award funds research to build evidence for clinical treatment decisions regarding extended-release (XR) buprenorphine injection versus daily sublingual buprenorphine for opioid use disorder (OUD). The project...
- This Project Grant from the National Institutes of Health National Institute on Drug Abuse, under the Drug Abuse and Addiction Research Programs (CFDA 93.279), provides $640,000 to Olfa Thera, Inc. to develop new therapeutics targeting the OLFR78/OR51E2 receptor pathway in the carotid body. The goal is to identify OLFR78/OR51E2 agonists that can strongly stimulate carotid body activity and ventilation to reverse opioid-induced respiratory depression, without the side effects of existing...
- This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $405,625.00 to Florida International University to investigate the potential benefits of the autophagy activator TFEB in mitigating opioid use disorder (OUD) and overdose in mice. The research aims to evaluate how TFEB overexpression or knockdown impacts opioid-induced effects on mu-opioid receptor desensitization, internalization, and...